How Long Does a Typhoid Vaccine Last?

How long a typhoid vaccine lasts depends on which vaccine you received. The injectable Vi polysaccharide shot protects for roughly two to three years before a booster is needed. The oral live vaccine (Ty21a) holds up longer, with protection persisting five to seven years. And the newer typhoid conjugate vaccines, now rolling out widely in endemic countries, show strong protection for at least four years, though immunity starts to fade after about five. These are meaningfully different timelines, and the choice of vaccine shapes not just your initial protection but your revaccination schedule for years to come.

The Injectable Vi Polysaccharide Shot

The Vi polysaccharide vaccine, sold under names like Typhim Vi, is the shot most commonly given at travel clinics. It works by presenting the Vi capsular sugar that coats the surface of Salmonella Typhi, prompting your immune system to produce antibodies against it. The catch is that polysaccharide vaccines do not generate strong immune memory the way protein-based vaccines do. Your antibody levels start high and then gradually slide downward.

A study tracking 37 adults in a non-endemic area found that anti-Vi antibody levels declined progressively over three years, supporting the current U.S. recommendation to get a booster every two years if you remain at risk.¹ Separate clinical data showed that mean Vi antibody levels remain significantly elevated for up to 34 months after a primary dose, and that both primary and booster doses are well tolerated in healthy adults.²

In terms of actual disease prevention, a large randomized trial in an endemic setting found the Vi polysaccharide vaccine was about 55% effective over three years, with no significant drop-off year by year during that period.³ That 55% figure is decent but not spectacular. It means even fully vaccinated travelers should still be careful about food and water hygiene in high-risk areas. The two-year booster schedule exists because antibody waning in people who live outside endemic areas is faster and more predictable than in people who get natural exposure to the bacteria, which can effectively “top up” their immunity.

The Oral Ty21a Vaccine

The oral typhoid vaccine uses a live but weakened strain of Salmonella Typhi called Ty21a. You take it as a series of capsules on alternate days. Because it mimics a mild intestinal infection, it activates parts of the immune system that the injectable shot does not reach, including mucosal immunity in the gut. This broader immune response is one reason it tends to last longer.

Long-term surveillance data from controlled field trials showed that three doses of Ty21a in enteric-coated capsules provided about 67% protection over three years and 62% protection over seven years. A liquid formulation of the same vaccine gave 77% protection over three years and 78% over five years.⁴ The fact that efficacy barely budged between three and seven years in the capsule formulation is remarkable. It suggests the immune memory generated by a live oral vaccine is qualitatively different from what the polysaccharide shot produces.

Because of this durability, the standard recommendation is to get a Ty21a booster every five years rather than every two. In practice, the oral vaccine is popular with travelers who dislike needles or who want longer-lasting protection with fewer clinic visits. But it does come with constraints: the capsules need refrigeration, you have to take them on an empty stomach over the course of a week, and you should avoid antibiotics and the antimalarial mefloquine during the dosing period because they can kill the live bacteria before they do their job.

Typhoid Conjugate Vaccines and Why They Changed the Game

Typhoid conjugate vaccines, often abbreviated as TCVs, represent a significant step forward. They link the Vi polysaccharide to a carrier protein, which transforms the immune response from a short-lived antibody bump into something that involves immune memory cells. This is the same conjugation principle behind the hugely successful meningococcal and pneumococcal vaccines used in childhood immunization programs worldwide.

The most widely studied TCV, Typbar-TCV, showed an overall efficacy of about 78% against blood-culture-confirmed typhoid over a median follow-up of roughly four years in a phase 3 trial among children in Malawi.⁵ A separate analysis of the same trial using different statistical methods confirmed vaccine efficacy of about 80% at three or more years after vaccination.⁶ That 78–80% efficacy figure is substantially better than what the older polysaccharide vaccine achieves, and it holds up over a longer window.

Another TCV product, TYPHIBEV (a Vi-CRM197 conjugate), has also demonstrated high effectiveness over 30 months of follow-up after national introduction in Nepal, with results comparable to Typbar-TCV.⁷ The evidence is building that conjugate technology produces consistently strong and durable results across different products and populations.

The WHO prequalified the first TCV in 2017 and now recommends it for routine immunization of children starting at six months of age in endemic countries, a population the older vaccines could not effectively target. Gavi, the global vaccine alliance, has supported TCV introduction in dozens of countries, and modeling studies predict that routine vaccination plus a catch-up campaign could reduce typhoid cases by a third to as much as 90% over a decade, depending on how long protection actually lasts.⁸

Why Age Matters for How Long Protection Lasts

One of the more important findings about TCV durability is that it varies by age at vaccination. A study in Hyderabad, Pakistan tracked children for four years after a single dose. Nearly all participants (about 96%) showed seroconversion within weeks, but the picture diverged over time. Among children older than five, roughly 83% remained above the protective antibody threshold at four years. For children between two and five, the figure was about 78%. But for children vaccinated at age two or younger, only about 63% stayed above that threshold.⁹

A review of available data on TCVs confirmed this pattern, finding that while the vaccines are effective overall, immunity wanes after about five years, with the fastest decline in children under two.¹⁰ The younger immune system is paradoxically both more responsive in the short term (infants had the highest initial seroconversion rates) and less capable of maintaining that response over time. This has real implications for vaccination policy. If the youngest children need a booster after a few years, the cost and logistics of typhoid programs in low-resource settings become more complicated.

Whether a booster will be officially recommended for TCVs is still an open question. The trials that would answer it are ongoing, and for now the WHO’s position is that a single dose is the standard schedule. But the data from Pakistan and Malawi strongly suggest that a booster conversation is coming, particularly for children vaccinated in infancy.

The Puzzle of Natural Boosting in Endemic Areas

An interesting wrinkle in the duration question is what happens when vaccinated people continue to live in areas where typhoid is common. A study of South African schoolchildren found that more than half of Vi-vaccinated children still had protective antibody levels a full ten years after vaccination. However, unvaccinated children in the same area had similarly high antibody levels. The researchers concluded that ongoing exposure to Salmonella Typhi in the environment was acting as a natural booster, maintaining antibody production in both groups.¹¹

This has an underappreciated practical implication. The duration figures from clinical trials in endemic countries may overestimate how long vaccines protect travelers, who return home to non-endemic settings and get no natural boosting. Conversely, people living in endemic areas may enjoy a kind of hybrid immunity where the vaccine primes the pump and repeated low-level exposure keeps it running. The two-year booster schedule for the Vi polysaccharide vaccine in the U.S. partly reflects this reality: without natural re-exposure, antibodies fade faster.

No Agreed-Upon “Magic Number” for Protection

One reason duration estimates remain somewhat fuzzy is that researchers still do not have a universally accepted antibody level that guarantees protection against typhoid. The 1 microgram per milliliter threshold for Vi antibodies has been used in several studies as a benchmark, but it is an estimate derived from correlating antibody levels with disease outcomes in specific populations, not a hard biological cutoff.³ A study of Vi-TT conjugate vaccination in Bangladeshi children noted that while antibody data is useful, there is no accepted serological threshold of protection yet established.¹²

This gap matters because antibodies are only part of the story. Conjugate and live oral vaccines also generate memory B and T cells, which can rapidly produce new antibodies when the real pathogen shows up, even if circulating antibody levels have dropped below a detectable threshold.¹³ Someone whose blood test shows low Vi antibodies might still be well protected because their immune system remembers the antigen and can mount a rapid defense. This is probably why the oral Ty21a vaccine maintained 62% efficacy at seven years even as measurable antibodies faded; the mucosal memory cells were doing the heavy lifting.

Cross-Protection Against Paratyphoid Fever

Travelers to South Asia sometimes worry about paratyphoid fever, caused by related bacteria called Salmonella Paratyphi A and B. The oral Ty21a vaccine offers a partial bonus here: field trials showed it provides meaningful cross-protection against Paratyphi B, though not against Paratyphi A. A study of the immune response in vaccinated adults found that Ty21a triggered antibody-producing cells that recognized Paratyphi B’s surface molecules reasonably well, but the response to Paratyphi A was significantly weaker.¹⁴ This cross-protection does not change the duration of anti-typhoid immunity, but it adds a practical reason some clinicians prefer the oral vaccine for travelers heading to regions where both typhoid and paratyphoid are circulating.

Research into the T-cell side of this cross-reactivity has found that Ty21a does trigger some immune cell responses against Paratyphi A, which has raised hopes for developing a combined vaccine targeting both organisms.¹⁵ For now, though, no licensed vaccine reliably prevents Paratyphi A infection.

How Cost-Effectiveness Models Use Duration Estimates

For public health planners in endemic countries, the duration of vaccine protection is not just a clinical question but an economic one. Modeling studies that compare typhoid vaccination strategies consistently identify duration of protection as one of the most influential variables in determining whether a program is worth the investment.¹⁶ If TCVs protect for a mean of 19 years (the optimistic scenario used in some models), routine childhood vaccination could cut typhoid cases by up to 46% over a decade. If protection lasts only about 6 years (the pessimistic scenario), the reduction drops to as low as 2–16%.⁸

Even under pessimistic assumptions, vaccination programs were predicted to be cost-effective in high-incidence settings. A modeling study supported by Gavi found that routine vaccination with a catch-up campaign was the optimal strategy in most eligible countries, with cost-effectiveness most clearly established where incidence exceeded 300 cases per 100,000 person-years.¹⁷ The fact that these programs pencil out even with short-duration assumptions reflects the sheer burden of typhoid in places where clean water infrastructure is lacking.

Practical Storage Concerns and Vaccine Potency

Duration of protection can also be affected by something more mundane than immunology: cold chain integrity. Both the injectable and oral vaccines need proper refrigeration to maintain potency. If a vaccine vial sits in a warm shipping container or a clinic without reliable power, the active components can degrade, and you might receive a less effective dose than expected. Research into heat-stable formulations of Ty21a-based vaccines has shown promising results for room-temperature storage, which could reduce the risk of potency loss during shipping to hot climates or in emergency scenarios.¹⁸ For travelers, this is mostly a non-issue at established clinics in high-income countries. But for mass vaccination campaigns in rural tropical settings, it can affect real-world durability in ways that clinical trial data, collected under ideal conditions, would not capture.

Giving Typhoid Vaccines Alongside Other Shots

Parents and travelers alike often wonder whether getting a typhoid vaccine at the same time as other vaccines could weaken the response or shorten how long protection lasts. A randomized trial in Burkina Faso tested TCV co-administered with measles-rubella and yellow fever vaccines at the routine nine-month visit and found that TCV produced a robust immune response without interfering with the other vaccines.¹⁹ This is reassuring for immunization programs that need to fit typhoid vaccination into an already crowded childhood schedule. For adult travelers getting a handful of shots before a trip, the same principle generally applies: the typhoid vaccine works fine alongside hepatitis A, yellow fever, and other travel vaccines without compromising its duration of protection.

Why Whole-Cell Typhoid Vaccines Disappeared

If you read older travel medicine references, you might come across mentions of a whole-cell killed typhoid vaccine that required multiple painful injections and was known for causing fevers and injection-site reactions. A systematic review and meta-analysis of typhoid vaccine trials noted that the whole-cell vaccine is considered unsuitable for public health use due to high rates of local and systemic side effects, and it is no longer manufactured.²⁰ Its disappearance is worth knowing about only because it explains why the current vaccines are sometimes described as “newer” even though Ty21a has been around since the 1980s and the Vi polysaccharide since the early 1990s. Compared to what came before, they are all improvements in both tolerability and convenience.